Literature DB >> 19427669

IMP3 expression in non-small cell lung cancer.

Guido Bellezza, Antonio Cavaliere, Angelo Sidoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19427669     DOI： 10.1016/j.humpath.2009.03.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN： 0046-8177            Impact factor:   3.466


× No keyword cloud information.
  11 in total

1.  IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes.

Authors:  Alessandro Del Gobbo; Annamaria Morotti; Anna Eleonora Colombo; Valentina Vaira; Giulia Ercoli; Chiara Pesenti; Eleonora Bonaparte; Elena Guerini-Rocco; Andrea Di Cristofori; Marco Locatelli; Alessandro Palleschi; Stefano Ferrero
Journal:  Med Oncol       Date:  2017-12-01       Impact factor: 3.064

2.  Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.

Authors:  Valerie N Barton; Andrew M Donson; Diane K Birks; Bette K Kleinschmidt-DeMasters; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

3.  Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.

Authors:  Xiangjie Sun; Ping Wei; Chen Shen; Yusi Yang; Yiqin Wang; Yuan Li; Xiang Du
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

4.  IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.

Authors:  Jinhai Yan; Qingzhu Wei; Wenjing Jian; Bo Qiu; Jing Wen; Jianghuan Liu; Bo Fu; Xinhua Zhou; Tong Zhao
Journal:  Lung       Date:  2015-11-25       Impact factor: 2.584

5.  Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.

Authors:  Kristian Ikenberg; Florian R Fritzsche; Ursina Zuerrer-Haerdi; Irina Hofmann; Thomas Hermanns; Helge Seifert; Michael Müntener; Maurizio Provenzano; Tullio Sulser; Silvia Behnke; Josefine Gerhardt; Ashkan Mortezavi; Peter Wild; Ferdinand Hofstädter; Maximilian Burger; Holger Moch; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

6.  Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.

Authors:  Ramaswamy Suvasini; Bhargava Shruti; Balaram Thota; Sridevi Vijay Shinde; Dinorah Friedmann-Morvinski; Zahid Nawaz; Krishnarao Venkatesh Prasanna; Kandavel Thennarasu; Alangar Sathyaranjandas Hegde; Arimappamagan Arivazhagan; Bangalore Ashwathnarayanarao Chandramouli; Vani Santosh; Kumaravel Somasundaram
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

7.  The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB.

Authors:  Dominik Schmiedel; Julie Tai; Rachel Yamin; Orit Berhani; Yoav Bauman; Ofer Mandelboim
Journal:  Elife       Date:  2016-03-16       Impact factor: 8.140

8.  IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.

Authors:  Feiya Yang; Qiang Zhou; Lingquan Meng; Nianzeng Xing
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

9.  IMP3 can predict aggressive behaviour of lung adenocarcinoma.

Authors:  Renata Beljan Perak; Merica Glavina Durdov; Vesna Capkun; Veljka Ivcevic; Antonia Pavlovic; Violeta Soljic; Mari Peric
Journal:  Diagn Pathol       Date:  2012-11-28       Impact factor: 2.644

Review 10.  Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?

Authors:  Jessica L Bell; Kristin Wächter; Britta Mühleck; Nikolaos Pazaitis; Marcel Köhn; Marcell Lederer; Stefan Hüttelmaier
Journal:  Cell Mol Life Sci       Date:  2012-10-16       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.